The Ministry of Health (MOH) has appointed a 14-member Expert Committee on COVID-19 Vaccination to make recommendations to the government on Singapore’s COVID-19 vaccination strategy, and ensure the safe and effective use of COVID-19 vaccines in the nation’s population.
The Expert Committee is chaired by Associate Professor Benjamin Ong, Senior Advisor to the Director of Medical Services, Ministry of Health, and Senior Vice President (Health Education and Resources), National University of Singapore. It also comprises experts in infectious diseases, immunology and other relevant fields.
The Expert Committee will leverage scientific and clinical expertise to assess vaccine candidates, and recommend the appropriate vaccines for use against COVID-19 in Singapore when they become available.
Further, it will consider the most up-to-date information and assessment of COVID-19 vaccines, including closely monitoring the global vaccine development landscape and stance of authoritative agencies such as the World Health Organization (WHO).
As the latest clinical data of vaccine candidates emerges, the Expert Committee will assess their safety, efficacy and suitability for use by the different segments of Singapore’s population. It will then make recommendations on the administration of vaccines to specific segments of the population and advise on the overall vaccination strategy for Singapore.
MOH said yesterday (12 Nov) that the Expert Committee convened their first meeting on 13 October 2020 and has met regularly in the past month to discuss the profiles of various vaccine candidates, as well as the conditions for their deployment in Singapore’s context.
Committee chair, A/Prof Benjamin Ong said, “Globally, as more vaccine candidates are made available for clinical use, ensuring that vaccines are safe and effective will be a top priority. There are many factors to consider as not all vaccines would be suitable, safe and effective for all segments of our population.
“The Expert Committee will need to closely study the safety and clinical data as they become available, while taking into account our local context, so that we can assess and recommend an appropriate and holistic vaccination strategy that can be put in place for the Singapore population.”
He added: “The safety of Singaporeans is our top priority, and the diverse range of expertise among my colleagues in the Expert Committee will put us in good stead as we deliberate on strategies for the implementation of COVID-19 vaccination in Singapore.”
MOH said that it has been actively monitoring the global progress in COVID-19 vaccine development, and has taken steps to secure access to a portfolio of vaccines for the population amidst expected strong global demand. It said: “We are a strong supporter and active participant in driving the work of the global COVID-19 Vaccine Global Access (COVAX) Facility.
“On top of our efforts through the COVAX Facility, we have further broadened and diversified our COVID-19 vaccine portfolio with a number of pharmaceutical companies which currently have vaccine candidates in development, so as to improve our chances of securing a suitable vaccine for Singapore.”
MOH promised to continue to closely track the progress of the different COVID-19 vaccine candidates under development globally in the coming months, and will provide further updates on its plans.
Follow us on Social Media
Send in your scoops to firstname.lastname@example.org